IN8bio Reports Upcoming Presentation Of Updated Results From Its Fully Enrolled Phase 1 Study Of INB-200 At ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
IN8bio will present updated results from its fully enrolled Phase 1 study of INB-200 at the ASCO meeting. INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a potential first-line treatment for newly diagnosed glioblastoma multiforme (GBM).
May 23, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio will present updated results from its Phase 1 study of INB-200 at the ASCO meeting. This could generate positive investor sentiment and potentially drive the stock price up.
The presentation of updated Phase 1 results at a major conference like ASCO can generate significant investor interest and optimism, potentially driving the stock price up. The focus on a novel treatment for GBM, a serious condition, adds to the potential positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100